Interpace Pancreas Test Reimbursement Code Changed | GenomeWeb

This article has been updated from a previous version to clarify that the Interpace test was assigned a different, existing CPT code.

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that its Medicare administrative carrier Novitas Solutions has assigned a different molecular CPT code to the molecular diagnostic firm's PancraGen test for pancreatic cysts, which is expected to improve reimbursement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.